You are here

PLoS medicine DOI:10.1371/journal.pmed.0020313

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

Publication TypeJournal Article
Year of Publication2005
AuthorsGreulich, H, Chen, TH, Feng, W, Jänne, PA, Alvarez, JV, Zappaterra, M, Bulmer, SE, Frank, DA, Hahn, WC, Sellers, WR, Meyerson, M
JournalPLoS medicine
Volume2
Issue11
Pagese313
Date Published2005/11/01
ISSN1549-1277
Abstract

Somatic mutations in the kinase domain of the epidermal growth factor receptor tyrosine kinase gene EGFR are common in lung adenocarcinoma. The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described.

URLhttp://dx.plos.org/10.1371/journal.pmed.0020313
DOI10.1371/journal.pmed.0020313
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/16187797?dopt=Abstract